anthera I sat down with the ceo and cfo at a deutche bank conference a few months ago. They had the drug for acs and another one for lupus. I told them if they only did the trial for lupus and dropped acs I would buy the stock. they have absolutely no data that tells me that their acs trial has a chance. the lupus drug looks like a better version of the hgsi compound